春興精工(002547.SZ):控股股東被動減持3.11%股份
格隆匯6月22日丨春興精工(002547.SZ)公佈,此前披露,公司控股股東孫潔曉因與國泰君安證券股份有限公司質押式回購業務違約糾紛,上海金融法院於2021年4月20日10時起至2021年4月21日10時止(延時除外)在淘寶網拍賣平台公開拍賣孫潔曉先生持有的公司股份共7026萬股(均分為兩筆,各3513萬股)。
公司於2021年6月21日收到控股股東孫潔曉提交的《簡式權益變動報吿書》,並於今日通過中國證券登記結算有限責任公司深圳分公司系統查詢,獲悉顧斌所競得的3513萬股公司股票(減持股份佔總股本3.11%)已完成過户登記手續。截至該公吿日,公司尚未取得上述股份過户的法律證明文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.